

Alyssa R Golden

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3251629/alyssa-r-golden-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

27
papers

931
citations

14
h-index

29
g-index

29
ext. papers

1,190
ext. citations

6.5
avg, IF

3.84
L-index

#	Paper	IF	Citations
27	Activity of cefepime/taniborbactam and comparators against whole genome sequenced ertapenem-non-susceptible Enterobacterales clinical isolates: CANWARD 2007-19.. <i>JAC-Antimicrobial Resistance</i> , 2022 , 4, dlab197	2.9	2
26	Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.. <i>Drugs</i> , 2022 , 1	12.1	3
25	Comparison of PCV-10 and PCV-13 vaccine coverage for invasive pneumococcal isolates obtained across Canadian geographic regions, SAVE 2011 to 2017. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021 , 99, 115282	2.9	2
24	Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia. <i>Drugs</i> , 2021 , 81, 233-256	12.1	10
23	ESBL-positive Escherichia coli and Klebsiella pneumoniae isolates from across Canada: CANWARD surveillance study, 2007-18. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 2815-2824	5.1	0
22	Comparison of phenotypic antimicrobial susceptibility testing results and WGS-derived genotypic resistance profiles for a cohort of ESBL-producing Escherichia coli collected from Canadian hospitals: CANWARD 2007-18. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 2825-2832	5.1	2
21	In vitro activity of imipenem-relebactam against various resistance phenotypes/genotypes of Enterobacterales and Pseudomonas aeruginosa isolated from patients across Canada as part of the CANWARD study, 2016-2019. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021 , 101, 115418	2.9	2
20	Whole genome characterization of Streptococcus pneumoniae from respiratory and blood cultures collected from Canadian hospitals before and after PCV-13 implementation in Canada: Focus on serotypes 22F and 33F from CANWARD 2007-2018. <i>Vaccine</i> , 2021 , 39, 5474-5483	4.1	0
19	Use of Fosfomycin Etest To Determine Susceptibility of Clinical Isolates of Other than Escherichia coli, Nonfermenting Gram-Negative Bacilli, and Gram-Positive Cocci. <i>Journal of Clinical Microbiology</i> , 2021 , 59, e0163521	9.7	1
18	Invasive pneumococcal disease caused by serotypes 22F and 33F in Canada: the SAVE study 2011-2018. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021 , 101, 115447	2.9	1
17	Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. <i>Drugs</i> , 2020 , 80, 285-313	3.1	32
16	In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020 , 97, 115012	2.9	23
15	Trends in antimicrobial resistance over 10 years among key bacterial pathogens from Canadian hospitals: results of the CANWARD study 2007-16. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, iv22-iv31	5.1	9
14	Comparison of antimicrobial resistance patterns in Streptococcus pneumoniae from respiratory and blood cultures in Canadian hospitals from 2007-16. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, iv39-iv47	5.1	12
13	42936 pathogens from Canadian hospitals: 10 years of results (2007-16) from the CANWARD surveillance study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, iv5-iv21	5.1	21
12	Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. <i>Drugs</i> , 2019 , 79, 271-289	12.1	160
11	Antimicrobial-resistant pathogens in Canadian ICUs: results of the CANWARD 2007 to 2016 study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 645-653	5.1	14

10	Analysis of multidrug resistance in the predominant <i>Streptococcus pneumoniae</i> serotypes in Canada: the SAVE study, 2011-15. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, vii12-vii19	5.1	30
9	Molecular characterization of predominant <i>Streptococcus pneumoniae</i> serotypes causing invasive infections in Canada: the SAVE study, 2011-15. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, vii20-vii31	5.1	18
8	Antimicrobial susceptibility testing of invasive isolates of <i>Streptococcus pneumoniae</i> from Canadian patients: the SAVE study, 2011-15. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, vii5-vii11	5.1	9
7	Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem- β -Lactamase Inhibitor Combinations. <i>Drugs</i> , 2018 , 78, 65-98	12.1	202
6	Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent. <i>Drugs</i> , 2016 , 76, 567-88	12.1	144
5	Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia. <i>Drugs</i> , 2016 , 76, 1737-1757	12.1	27
4	Invasive <i>Streptococcus pneumoniae</i> in Canada, 2011-2014: Characterization of new candidate 15-valent pneumococcal conjugate vaccine serotypes 22F and 33F. <i>Vaccine</i> , 2016 , 34, 2527-30	4.1	24
3	Assessment of multidrug resistance, clonality and virulence in non-PCV-13 <i>Streptococcus pneumoniae</i> serotypes in Canada, 2011-13. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 1960-4	5.1	26
2	Characterization of MDR and XDR <i>Streptococcus pneumoniae</i> in Canada, 2007-13. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 2199-202	5.1	48
1	Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens. <i>Drugs</i> , 2015 , 75, 253-70	12.1	107